Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi Sells 5,980 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,980 shares of Sight Sciences stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $13,754.00. Following the completion of the transaction, the chief technology officer now directly owns 1,836,704 shares in the company, valued at $4,224,419.20. This represents a 0.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Badawi also recently made the following trade(s):

• On Friday, January 17th, David Badawi sold 5,423 shares of Sight Sciences stock. The shares were sold at an average price of $2.78, for a total transaction of $15,075.94.
• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The stock was sold at an average price of $3.26, for a total transaction of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The shares were sold at an average price of $3.52, for a total transaction of $10,950.72.

Sight Sciences Trading Up 3.1 %

Shares of SGHT opened at $2.30 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. Sight Sciences, Inc. has a one year low of $2.04 and a one year high of $8.45. The stock has a 50-day moving average price of $2.67 and a 200 day moving average price of $3.86. The company has a market capitalization of $118.07 million, a P/E ratio of -2.25 and a beta of 2.52.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). The company had revenue of $19.07 million for the quarter, compared to analyst estimates of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same period in the previous year, the business posted ($0.22) EPS. Sell-side analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. KCK LTD. acquired a new position in Sight Sciences in the fourth quarter worth about $15,925,000. Barclays PLC lifted its holdings in Sight Sciences by 317.4% during the 3rd quarter. Barclays PLC now owns 50,300 shares of the company’s stock worth $317,000 after buying an additional 38,248 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after acquiring an additional 12,709 shares in the last quarter. State Street Corp increased its holdings in shares of Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after acquiring an additional 95,843 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Sight Sciences by 46.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock valued at $1,310,000 after acquiring an additional 65,767 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Stifel Nicolaus lowered their price target on Sight Sciences from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Lake Street Capital lowered their target price on Sight Sciences from $3.00 to $2.50 and set a “hold” rating for the company in a research note on Thursday, March 6th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a report on Thursday, March 6th. UBS Group decreased their price target on Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a report on Monday, January 27th. Finally, Citigroup dropped their price objective on shares of Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.83.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.